Pushing the boundaries of
innovation in oncology.
innovation in oncology.
Pushing the boundaries of
innovation in oncology.
innovation in oncology.
About
There is more innovation in cancer research today than ever before. Many of these efforts are disjointed and silo-ed and as a result often do not reach their full potential. If we can capture that potential, there is great opportunity for cancer patients.
Cullinan uniquely applies open innovation to the development of scientific oncology assets. Our approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, we seek to develop first-in-class or best-in-class assets that have the potential to significantly improve the lives of those living with cancer.
Drug development through
the prism of modern-day
portfolio management.
the prism of modern-day
portfolio management.
Our Approach
Cullinan was formed to advance a growing portfolio of innovative, early-stage assets by capitalizing on the latest scientific breakthroughs. The company is structured as a unique hybrid model that brings together certain aspects of an investment firm with a true operating company. As a result, we think about capital allocation and risk as much as we think about in-vivo results or clinical trial design.
- Access to the world’s earliest stage oncology research through relationships with MPM Capital, academia, and pharma
- Portfolio diversification across platforms, mechanisms and modalities
- Led by a team of veteran oncology researchers, biopharma executives, and experienced entrepreneurs
Team
At the core of any great company is its people. The Cullinan team is a group of accomplished professionals that share a vision for eradicating cancer.
Board of Directors
Investors
Most recently, Kerry was Director of Discovery and Translational Biology, and led multiple oncology programs. She held prior positions at both Aveo and Wyeth, and her drug development background spans preclinical to Phase 2 assets and includes biologics, ADC’s, and small molecules.
Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics (NASDAQ:MGNX), where he led the company’s evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. This included the translation of ten new molecules into the clinic, including early phase and/or proof-of-concept studies with bispecific molecules, checkpoint inhibitors, Fc-optimized antibodies and antibody drug conjugates, as well as the design and execution of registration-directed studies.
Erica is an Executive Assistant and Office Supervisor at Cullinan Oncology.
